Navigation Links
OncoGenex Pharmaceuticals announces out-license of TOCOSOL Paclitaxel to Eagle Pharmaceuticals
Date:9/2/2008

BOTHELL, WA and VANCOUVER, Sept. 2 /PRNewswire-FirstCall/ - OncoGenex Pharmaceuticals, Inc. (NASDAQ: OGXI) ("OncoGenex" or the "Company") has announced today that it has granted to Eagle Pharmaceuticals, Inc. the exclusive worldwide rights to develop and commercialize TOCOSOL(R) Paclitaxel. Under the terms of the agreement, OncoGenex is entitled to receive royalty payments from future TOCOSOL Paclitaxel sales and a percentage of sub-licensing royalty and milestone payments received by Eagle Pharmaceuticals. All development expenses are the sole responsibility of Eagle Pharmaceuticals. No upfront payments or milestone payments were included in this transaction and no further terms have been disclosed.

TOCOSOL Paclitaxel was previously developed by Sonus Pharmaceuticals prior to the combination of Sonus and OncoGenex Technologies to form the Company on August 21, 2008. In previous disclosures, the Company stated that it had terminated further development of TOCOSOL Paclitaxel and would evaluate alternative strategies for the program, including out-licensing.

"We intend to focus all of our efforts on the deep pipeline we currently have in development, including OGX-011 which is completing five Phase 2 clinical studies in prostate, breast and lung cancers," said Scott Cormack, President and CEO of OncoGenex Pharmaceuticals. "TOCOSOL Paclitaxel was not part of that strategy, and we are pleased to be able to out-license the program to an organization with interest in continuing development of this product candidate."

About OncoGenex Pharmaceuticals

OncoGenex Pharmaceuticals is a biopharmaceutical company committed to the development and commercialization of new cancer therapies that address unmet needs in the treatme
'/>"/>

SOURCE OncoGenex Pharmaceuticals, Inc.
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3

Related biology technology :

1. FDA Grants Fast Track Designation for OncoGenex Pharmaceuticals Lead Product Candidate OGX-011
2. Sonus Pharmaceuticals and OncoGenex Technologies complete business combination; OncoGenex Pharmaceuticals to commence trading on NASDAQ Capital Market today
3. OncoGenex receives completed Special Protocol Assessment for primary registration study of lead drug candidate OGX-011
4. OncoGenex increases economic interest in lead cancer drug OGX-011
5. OncoGenex to present at the Needham & Company 7th Annual Biotechnology & Medical Technology Conference
6. Sonus Pharmaceuticals and OncoGenex Technologies to Merge
7. OncoGenex reports lead drug candidate OGX-011 achieved primary endpoint in Phase 2 Trial with second-line chemotherapy for prostate cancer
8. Amylin Pharmaceuticals to Present at Thomas Weisel Healthcare, BioCentury NewsMakers, and Morgan Stanley Global Healthcare Conferences
9. Arena Pharmaceuticals to Present at the NewsMakers in the Biotech Industry Conference
10. Cadence Pharmaceuticals CEO Theodore Schroeder to Present at the 2008 NewsMakers In the Biotech Industry Conference
11. Trubion Pharmaceuticals to Present at Fall 2008 Morgan Stanley Global Healthcare Unplugged Conference in New York
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:8/29/2014)... Due to a misstatement posted by the ... Cell Technology Center, LLC ( ASCTC ) was reported as ... that might benefit ALS patients. Because of ASCTC's exclusive ... technologies and therapeutic applications, FRC listed ASCTC as one of ... who wish not to support research that requires the death ...
(Date:8/28/2014)... 28, 2014 Best Sanitizers, Inc., a ... food processing industry, is asking industry professionals to prepare ... of the E2 soap they’re currently using to the ... . Hand hygiene is critical to fighting cross-contamination ... environment. Six key criteria are identified to evaluate the ...
(Date:8/28/2014)... devices in spintronics, an electronic which is not ... also on their spin and the spin-related magnetism. ... magnetic signals and vice versa. Recently, the research ... of Physics at Johannes Gutenberg University Mainz in ... Japan, has for the first time realised a ...
(Date:8/28/2014)... SunTrust Robinson Humphrey (STRH) today announced the ... research team in biotechnology and oilfield services.  ... demonstrates our commitment to providing our valued institutional ... decision making," said Biff Woodruff , Head ... significant investments in differentiated content at a time ...
Breaking Biology Technology:The Adult Stem Cell Technology Center, LLC Declines ALS Ice Bucket Challenge Donors Wishing to Support Ethical Research for New Stem Cell Therapies 2The Adult Stem Cell Technology Center, LLC Declines ALS Ice Bucket Challenge Donors Wishing to Support Ethical Research for New Stem Cell Therapies 3Best Sanitizers, Inc. Asks Food Industry Professionals: With Fall Harvest On the Way, Is Your E2 Hand Soap Up to the Task? 2A new, tunable device for spintronics 2A new, tunable device for spintronics 3SunTrust Robinson Humphrey Expands Equity Research in Healthcare and Energy 2SunTrust Robinson Humphrey Expands Equity Research in Healthcare and Energy 3
(Date:8/28/2014)... at the University of Minnesota have developed an animal ... used for muscle regeneration research as well as studies ... The research is published in the current edition of ... no treatment for FSHD, which is thought by many ... FSHD is an unusual genetic disorder because, unlike most ...
(Date:8/28/2014)... compounds that could positively impact the global ... possible, thanks to researchers in Penn State,s ... suppository made from the seaweed-derived food ingredient ... Tenofovir provides a woman-initiated, drug-delivery vehicle that ... transmitted infections during unprotected heterosexual intercourse, the ...
(Date:8/28/2014)... new roads will be built worldwide by 2050. Many ... where they bring an influx of destructive loggers, hunters ... has created a ,global roadmap, for prioritising road building ... demands of development and environmental protection. , The map ... natural importance of ecosystems and a ,road-benefits, layer that ...
Breaking Biology News(10 mins):UMN researchers find animal model for understudied type of muscular dystrophy 2Sensory-tested drug-delivery vehicle could limit spread of HIV, AIDS 2Sensory-tested drug-delivery vehicle could limit spread of HIV, AIDS 3Study shows where on the planet new roads should and should not go 2Study shows where on the planet new roads should and should not go 3
... Hamilton, Nov. 11, 2013 Researchers at McMaster University have ... and it may serve as a way to measure injury. ... muscle damage biomarker," said Thomas Hawke, principal investigator and an ... at McMaster. "Regardless of the way in which ...
... after giving birth plays a big factor in the quantity and ... University of Missouri have found that subclinical hypocalcemia, which is the ... occurs in many cows after giving birth, is related to higher ... the MU College of Veterinary Medicine, says these higher levels of ...
... his sons less sensitive to the drug and thereby more ... animal study presented by Penn Medicine researchers at Neuroscience 2013, ... The study, led by Mathieu Wimmer, PhD, a post-doctoral researcher ... of Neuroscience in Psychiatry at the Perelman School of Medicine ...
Cached Biology News:Low levels of blood calcium in dairy cows may affect cow health and productivity, MU study finds 2Sons of cocaine-using fathers may resist addiction to drug, Penn Medicine study suggests 2
Mouse monoclonal [AZ24] to Polo like kinase ( Abpromise for all tested applications)....
... brings together two mature, well-understood technologies: ... surfaces. This combination produces a sensitive ... detection of molecular binding events without ... Protein-specific capture molecules are immobilized on ...
... LabWorks Software provides a comprehensive experiment based ... drop down menus yet sophisticated and powerful ... dozens of CCD cameras for easy image ... , Automated Digital Video Playback ...
RABBIT ANTI HUMAN ALPHA-2-ANTIPLASMIN...
Biology Products: